What's Behind This Huge SPDR S&P 500 ETF Trust (SPY) Trade?

It appears one SPDR S&P 500 ETF Trust (SPY) trader rolled down a massive put position in the quarterly 3/31 series

by Karee Venema

Published on Mar 27, 2015 at 10:21 AM
Updated on Apr 20, 2015 at 5:09 PM

Put players were active on the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) yesterday, with the contracts trading at 1.4 times the average daily rate, and outpacing calls by a 2-to-1 margin. Drilling down, our Senior VP of Research Todd Salamone noticed some interesting action at the quarterly 3/31 200- and 205-strike puts, where two symmetrical blocks of 40,000 contracts changed hands.

Drilling down, it appears as though the lower-strike puts were purchased, while the higher-strike puts were sold. Assuming this was a roll, the trader expects SPY to settle south of $200 at next Tuesday's close, when the quarterly series expires.

Salamone offered even more insight, explaining that a similarly sized block of 40,000 quarterly 3/31 205-strike puts was purchased on Feb. 17 for $2.52 apiece, and was sold yesterday for $1.71 each -- meaning the speculator may have incurred a loss. Meanwhile, he also noted that the sale of the near-the-money 205 puts appeared to have a coincident positive impact for the SPDR S&P 500 ETF Trust (NYSEARCA:SPY), as it occurred simultaneously with the fund's morning lows. This morning, SPY was last seen fractionally lower at $205.26.

30-Minute Chart of SPY Sine March 23

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Legendary Stock-Picker Calls Top Stock of 2020
Matt McCall's picks were met with disbelief... Until five soared over 1,000%. Get his latest 2020 pick.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.